AllPennyStocks.com CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics

The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.

Other Penny Stock Movers

Financial Tech Junior Surges 18% Following Reaffirmation of US$15.8M Digital Treasury
Quebec Gold Explorer Jumps 16% on C$57M Strategic Backing
$4.5 Million Could Unlock a Major Cannabis Market
Most Popular
{{ index + 1 }}


Back to Top